We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
- Authors
Escudier, B; Michaelson, M D; Motzer, R J; Hutson, T E; Clark, J I; Lim, H Y; Porfiri, E; Zalewski, P; Kannourakis, G; Staehler, M; Tarazi, J; Rosbrook, B; Cisar, L; Hariharan, S; Kim, S; Rini, B I
- Abstract
Background:In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.Methods:In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs ⩾median), and tumour burden (baseline sum of the longest diameter < vs ⩾median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated.Results:Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy.Conclusions:AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.
- Subjects
CANCER invasiveness; RENAL cell carcinoma; THERAPEUTIC use of cytokines; CANCER patients; ENDOTHELIAL growth factors; HEALTH outcome assessment
- Publication
British Journal of Cancer, 2014, Vol 110, Issue 12, p2821
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/bjc.2014.244